Trial Profile
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Trametinib (Primary)
- Indications Cholangiocarcinoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Jun 2019 The thyroid cancer cohort was terminated after planned interim analysis suggested insufficiently increased activity against the historical control of pazopanib alone, according to the results published in the Clinical Cancer Research.
- 11 Jun 2019 Safety and efficacy results from thyroid cancer cohort (n=26) published in the Clinical Cancer Research.
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.